Mar 10, 2020
Sirolimus Market Insights 2020-2025: Anticipating a CAGR of 4.1%, Worldwide
Jan 08, 2020
National Kidney Foundation's Dr. Matthew Cooper to Testify before Congress
Nov 08, 2019
Latest Developments in the Interleukin-2 (IL-2) Research and Development, 2019 Report
Oct 22, 2019
Organ Transplant Immunosuppressant Drugs Market Worth $5.88 Billion by 2026: Grand View Research, Inc.
Sep 04, 2019
The global kidney transplantation therapeutics market at a CAGR of over 4% during the forecast period
May 10, 2019
National Kidney Foundation Statement on Newly Released HHS Report on Cost Savings and Extending Immunosuppressive Drug Coverage for Transplant Patients
Mar 18, 2019
Astellas Launches PROGRAF® Granules (tacrolimus for oral suspension) in the U.S. for Pediatric Liver, Heart, and Kidney Transplant Patients
Feb 06, 2019
The global transplant market will reach $29bn in 2019
Dec 18, 2018
Global Transplant Complications Drug Development Pipeline Review 2018 Featuring Medeor Therapeutics, Amgen and Novartis
Nov 14, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights
Oct 24, 2018
First Head-to-Head Trial of a TNF Inhibitor Versus Methotrexate Monotherapy in Psoriatic Arthritis Shows ENBREL® (Etanercept) Monotherapy and Combination Therapy Both Superior to Methotrexate
Jul 05, 2018
Neovii & Mundipharma Confirm In-licensing Agreement for the Development and Promotion of Grafalon(R) in China and Japan for Solid Organ & Stem Cell Transplant
Jun 01, 2018
FDA Approves OLUMIANT® (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis
May 14, 2018
National Kidney Foundation Statement on American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs
Apr 20, 2018
FDA Accepts Veloxis's Supplemental New Drug Application for the De Novo Indication for ENVARSUS XR®
Mar 28, 2018
Veloxis Announces the Publication of ASERTAA (A Study of Extended Release Tacrolimus in African-Americans), a Phase IIIb study of ENVARSUS XR®
Mar 07, 2018
Veloxis Files with FDA for the De Novo Indication for ENVARSUS XR®
Sep 22, 2017
Immunoassays Show Strength: Watch These Three Areas